Niacin as antidyslipidemic drug. - Test2 - elhamkhani - TriplyDB

Niacin as antidyslipidemic drug.

Niacin as antidyslipidemic drug.

http://www.wikidata.org/entity/Q38586930

about

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.

P2860

Q28078664-0C73B43F-DBAA-4634-97CA-F04894E0878C Q49798045-C535A047-7C70-4EDA-A997-E73F1624440D Q55426305-E993B3A9-0A1E-4106-8097-F9FC75E1E1F8

P2860

Niacin as antidyslipidemic drug.

http://www.wikidata.org/entity/Q38586930

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Niacin as antidyslipidemic drug.

@en

type

label

Niacin as antidyslipidemic drug.

@en

prefLabel

Niacin as antidyslipidemic drug.

@en

P1433

Q38586930-AF5F5835-AF7B-4309-A411-437EB5671543

P1476

Q38586930-101612A1-9828-473B-A319-BA9E6F56D9A4

P2093

Q38586930-046F12FC-5CAB-4EA6-960B-143006540A70

P2860

Q38586930-01B1AFDF-04C0-4C48-859A-16BA45A2FF16

Q38586930-0993A822-3BC4-4139-96E4-AF9E2BF6E621

Q38586930-0B0ED7E0-8E94-441F-A23A-FB5F5E88E052

Q38586930-0C669DF3-AF7E-4ECB-84D5-D4ED3443D025

Q38586930-0E8CC81C-A9BA-4FFD-A963-1452D14259AD

Q38586930-100426DB-936A-451C-A8C2-A821278B3FF6

Q38586930-116128B3-EAFA-4162-BF0C-994F1224BD35

Q38586930-16642CEF-9BF4-45F5-A820-781C64F974FD

Q38586930-17A7D1CE-5ED0-48EA-86BB-0B33753B93CC

Q38586930-17B8BCA4-BBEA-47D2-8DEB-E099585E8FC6

P304

Q38586930-EAF38F46-7543-4453-9118-F46DF29676A2

P31

Q38586930-2C5FB80F-EF0D-423E-A7EE-83B5ADD681CA

P356

Q38586930-CFDBC144-DD8B-4D7E-8FCE-D64ED9E5E3F4

P433

Q38586930-CECFF399-2366-4501-AA00-C6038AD20C07

P478

Q38586930-24B6F965-05AB-4B4B-8494-C8B8DF9E0392

P577

Q38586930-0D701B4E-1673-4722-9776-517BB394A834

P698

Q38586930-6609DE20-D477-4861-AA65-245BF9C133C8

P356

P1433

Canadian Journal of Physiology and Pharmacology

P1476

Niacin as antidyslipidemic drug.

@en

P2093

Ulrich Julius

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid

Lipoprotein(a) as a cardiovascular risk factor: current status

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

The therapeutic role of niacin in dyslipidemia management

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms.

Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats.

Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathway.

P304

1043-1054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1139/CJPP-2014-0478

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26370906

http://www.w3.org/2001/XMLSchema#string